Cytokinetics, Incorporated

DB:KK3A Stock Report

Market Cap: €5.6b

Cytokinetics Future Growth

Future criteria checks 2/6

Cytokinetics is forecast to grow earnings and revenue by 36.7% and 67.6% per annum respectively while EPS is expected to grow by 39.5% per annum.

Key information

36.7%

Earnings growth rate

39.5%

EPS growth rate

Biotechs earnings growth42.4%
Revenue growth rate67.6%
Future return on equityn/a
Analyst coverage

Good

Last updated19 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:KK3A - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026327-473-522-41313
12/31/202555-628-636-56115
12/31/202414-588-428-43516
9/30/20243-576-407-404N/A
6/30/20243-545-401-399N/A
3/31/20244-531-423-422N/A
12/31/20238-526-416-414N/A
9/30/20238-527-443-438N/A
6/30/202310-540-437-426N/A
3/31/202398-431-406-395N/A
12/31/202295-389-311-300N/A
9/30/2022148-282-272-246N/A
6/30/2022151-216-236-201N/A
3/31/202265-258-183-140N/A
12/31/202170-215-191-143N/A
9/30/202122-229-83-46N/A
6/30/202158-156-178N/A
3/31/202159-135-710N/A
12/31/202056-127-29N/A
9/30/202054-114-68-62N/A
6/30/202019-140-101-97N/A
3/31/202022-132-98-94N/A
12/31/201927-122-94-91N/A
9/30/201931-118-86-84N/A
6/30/201936-110-97-96N/A
3/31/201935-105-99-98N/A
12/31/201832-106-102-101N/A
9/30/201822-120-114-113N/A
6/30/201818-131N/A-106N/A
3/31/201814-132N/A-111N/A
12/31/201713-128N/A-102N/A
9/30/201747-80N/A0N/A
6/30/201799-14N/A14N/A
3/31/20171023N/A34N/A
12/31/201610616N/A37N/A
9/30/2016830N/A-51N/A
6/30/201632-42N/A-49N/A
3/31/201633-41N/A-47N/A
12/31/201529-38N/A5N/A
9/30/201541-20N/A7N/A
6/30/201542-17N/A8N/A
3/31/201543-15N/A7N/A
12/31/201447-15N/A-45N/A
9/30/201450-17N/A-49N/A
6/30/201445-23N/A-29N/A
3/31/201438-30N/A-13N/A
12/31/201331-34N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KK3A is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KK3A is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KK3A is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KK3A's revenue (67.6% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: KK3A's revenue (67.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if KK3A's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y